

Substrate-Controlled Product-Selectivity in the Reaction of Bestmann-Ohira Reagent with *N*-Unprotected Isatin- Derived Olefins

Ashis Kumar Gupta, Shakir Ahamad, Ekta Gupta, Ruchir Kant and Kishor Mohanan*

Medicinal and Process Chemistry Division,

CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur road, Lucknow, India-
226031

kishor.mohanan@cdri.res.in

SUPPORTING INFORMATION

Content:

1. General experimental information (p. S2)
2. General Procedure (p. S3)
3. Characterization data for compounds **3a-3r**, **5a-5ad**, **7** & **8** (p. S4)
4. Copies of ^1H , ^{13}C and ^{31}P NMR spectra for all compounds (p. S32)

General experimental information:


Unless otherwise specified, all reactions were carried out under air atmosphere in oven-dried round-bottom flasks. Dimethyl 2-oxopropylphosphonate was purchased from Acros and was used without further purification. The reactions were monitored by TLC visualized by UV (254 nm) and/or with iodine. Flash chromatography was performed on 100-200 mesh silica gel using the gradient system acetone-dichloromethane (0-40%). NMR data were recorded at Bruker AV 400 MHz in DMSO- d_6 /CDCl $_3$ /CF $_3$ CO $_2$ D using as internal standards the residual DMSO signal for ^1H NMR (δ = 2.50 ppm), CHCl $_3$ (δ = 7.26 ppm) and CF $_3$ CO $_2$ H (δ = 11.50 ppm) respectively. The corresponding deuterated solvent signal for ^{13}C NMR were assigned as DMSO (δ = 39.51 ppm), CDCl $_3$ (77.16) and CF $_3$ CO $_2$ D (116.0). Coupling constants are given in Hertz (Hz) and the classical abbreviations are used to describe the signal multiplicities. Melting points were measured with a Büchi B-540 apparatus and are uncorrected. High resolution mass spectra were obtained using Q-TOF mass spectrometer. All commercially available reagents were used as received.

The Bestmann-Ohira reagent was synthesized from the corresponding Dimethyl 2-oxopropylphosphonate using a known procedure.¹

(1) P. Callant, L. Dhaenens and M. Vandewalle, *synth. Commun.*, **1984**, 14, 155.

Procedures


Synthesis of spiro-phosphonylpyrazoline-oxindoles 3a-3r



General procedure for the synthesis of spiroposphonylpyrazoline-oxindoles 3

To an oven-dried round bottom flask was added 3-benzylideneoxindole **1a** (50 mg, 0.22 mmol) and dissolved in 3 mL of MeOH. Subsequently, a solution of Bestmann-Ohira reagent (65 mg, 0.33 mmol) in 2 mL of MeOH was added to the reaction mixture and kept stirring. After addition of potassium hydroxide (25 mg, 0.44 mmol), the reaction mixture was further stirred at 25 °C for 1.5 h. After the completion of reaction, as indicated by TLC, solvent was evaporated off and extracted using ethyl acetate. The organic layer was dried over Na₂SO₄ and evaporated under reduced pressure. The residue was purified using column chromatography (100-200 mesh silica gel) using acetone/dichloromethane as the eluent to afford the corresponding spiropyrazoline-oxindole **3a** as a white solid (78 mg) in 95% yield.

Synthesis of spiro-phosphonylpyrazoline-oxindoles 5a-5ad




General procedure for the synthesis of phosphonylpyrazolo-quinazolinones 5

To an oven-dried round bottom flask was added 3-phenacylideneoxindole **4a** (50 mg, 0.20 mmol) and dissolved in 3 mL of MeOH. Subsequently, a solution of Bestmann-Ohira reagent


(58 mg, 0.30 mmol) in 2 mL of MeOH was added to the reaction mixture and kept stirring. After addition of potassium hydroxide (23 mg, 0.40 mmol), the reaction mixture was further stirred at 25 °C for 1 h. After the completion of reaction, as indicated by TLC, solvent was evaporated off and extracted using ethyl acetate. The organic layer was dried over Na₂SO₄ and evaporated under reduced pressure. The residue was purified using column chromatography (100-200 mesh silica gel) using acetone/dichloromethane as the eluent to afford phosphonylpyrazoloquinazolinone **5a** as a white solid (63 mg) in 80 yield.

Dimethyl (2-oxo-4'-phenyl-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (**3a**)



Following the general procedure, treatment of (benzylidene)indolin-2-one (50 mg, 0.22 mmol) with BOR (65 mg, 0.33 mmol) in the presence of KOH (25 mg, 0.44 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3a** as a white solid (78 mg, 95%, 5:1 dr). *R_f* (Acetone/Dichloromethane : 3/7) = 0.45. **Mp** 178-180 °C. ¹³C NMR (100 MHz, δ ppm/ DMSO-*d*₆): 178.0 (C), 142.3 (C), 141.6 (d, *J*_{C-P} = 227.2 Hz, C), 134.1 (C), 129.1 (C), 128.9 (CH), 128.9 (CH), 128.1 (CH), 128.1 (CH), 127.7 (CH), 125.6 (CH), 125.1 (CH), 120.9 (CH), 109.5 (CH), 73.8 (d, *J*_{C-P} = 4.7 Hz, C), 60.4 (d, *J*_{C-P} = 21.7 Hz, CH), 52.8 (d, *J*_{C-P} = 5.8 Hz, CH₃), 52.6 (d, *J*_{C-P} = 5.6 Hz, CH₃). ¹H NMR (400 MHz, δ ppm/DMSO-*d*₆): 10.38 (s, 1H), 9.00 (s, 1H), 7.24 (d, *J* = 6.4 Hz, 3H), 7.06-6.98 (m, 3H), 6.71 (d, *J* = 7.6 Hz, 1H), 6.54 (t, *J* = 7.4 Hz, 1H), 6.23 (d, *J* = 7.2 Hz, 1H), 4.54 (s, 1H), 3.66 (d, *J* = 11.2 Hz, 3H), 3.58 (d, *J* = 11.2 Hz, 3H). ³¹P NMR (161.9 MHz, DMSO-*d*₆): 10.83. **HRMS** for C₁₈H₁₉N₃O₄P⁺: calcd. [M+H]⁺: 372.1108, found: 372.1111.


Dimethyl (4'-(4-methoxyphenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (**3b**)



Following the general procedure, treatment of (4-methoxybenzylidene)indolin-2-one (50 mg, 0.20 mmol) with BOR (57 mg, 0.30 mmol) in the presence of KOH (22 mg, 0.40 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3b** as a white solid (74 mg, 92%, 4:1 dr). *R_f* (Acetone/Dichloromethane : 3/7) = 0.39. **Mp**

192-194 °C. ¹³C NMR (100 MHz, δ ppm/DMSO-*d*₆): 178.1 (C), 158.6 (C), 142.3 (C), 141.6 (d, *J*_{C-P} = 227.0 Hz, C), 130.2 (CH), 130.2 (CH), 129.1 (CH), 125.9 (CH), 125.7 (CH), 125.3 (C), 120.9 (CH), 113.4 (CH), 113.4 (CH), 109.4 (CH), 73.8 (d, *J*_{C-P} = 4.8 Hz, C), 59.8 (d, *J*_{C-P} = 21.8 Hz, CH), 54.9 (CH₃), 52.8 (d, *J*_{C-P} = 5.8 Hz, CH₃), 52.6 (d, *J*_{C-P} = 5.6 Hz, CH₃). ¹H NMR (400 MHz, δ ppm/DMSO-*d*₆): 10.39 (s, 1H), 9.0 (s, 1H), 7.05 (t, *J* = 7.8 Hz, 1H), 6.91 (d, *J* = 8.0 Hz, 2H), 6.80 (d, *J* = 8.4 Hz, 2H), 6.71 (d, *J* = 8.0 Hz, 1H), 6.59 (t, *J* = 7.4 Hz, 1H), 6.29 (d, *J* = 7.6 Hz, 1H), 4.49 (s, 1H), 3.69 (s, 3H), 3.62 (d, *J* = 11.2 Hz, 3H), 3.55 (d, *J* = 11.2 Hz, 3H). ³¹P NMR (161.9 MHz, DMSO-*d*₆): 10.85. HRMS for C₁₉H₂₁N₃O₅P⁺: calcd. [M+H]⁺: 402.1213, found: 402.1214.


Dimethyl(2-oxo-4'-(*p*-tolyl)-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3c)



Following the general procedure, treatment of (4-methylbenzylidene)indolin-2-one (50 mg, 0.21 mmol) with BOR (60 mg, 0.32 mmol) in the presence of KOH (23 mg, 0.42 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3c** as a white solid (74 mg, 90%, 9:1 dr). *R*_f (Acetone/Dichloromethane : 3/7) = 0.41. *Mp* 182-

184 °C. ¹³C NMR (100 MHz, δ ppm/ DMSO-*d*₆): 178.1 (C), 142.3 (C), 141.8 (d, *J*_{C-P} = 227.1 Hz, C), 136.7 (C), 131.0 (C), 129.1 (C), 128.9 (CH), 128.9 (CH), 128.6 (CH), 128.6 (CH), 125.7 (CH), 125.3 (CH), 120.9 (CH), 109.4 (CH), 73.9 (d, *J*_{C-P} = 4.8 Hz, C), 60.2 (d, *J*_{C-P} = 21.7 Hz, CH), 52.8 (d, *J*_{C-P} = 5.8 Hz, CH₃), 52.6 (d, *J*_{C-P} = 5.6 Hz, CH₃), 20.6 (CH₃). ¹H NMR (400 MHz, δ ppm/DMSO-*d*₆): 10.36 (s, 1H), 8.97 (s, 1H), 7.06-7.03 (m, 3H), 6.87 (d, *J* = 8.0 Hz, 2H), 6.70 (d, *J* = 8.0 Hz, 1H), 6.57 (t, *J* = 7.6 Hz, 1H), 6.29 (d, *J* = 7.6 Hz, 1H), 4.49 (s, 1H), 3.63 (d, *J* = 11.2 Hz, 3H), 3.54 (d, *J* = 11.2 Hz, 3H), 2.23 (s, 3H). ³¹P NMR (161.9 MHz, DMSO-*d*₆): 10.83. HRMS for C₁₉H₂₁N₃O₄P⁺: calcd. [M+H]⁺: 386.1264, found: 386.1263.


Dimethyl (4'-(4-ethylphenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3d)



Following the general procedure, treatment of (4-ethylbenzylidene)indolin-2-one (50 mg, 0.20 mmol) with BOR (57 mg, 0.30 mmol) in the presence of KOH (22 mg, 0.40 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3d** as a white solid (65 mg,

81%, 7:1 dr). **R_f** (Acetone/Dichloromethane : 3/7) = 0.42. **Mp** 166-168 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 178.1 (C), 143.1 (C), 142.3 (C), 141.7 (d, *J*_{C-P} = 227.6 Hz, C), 131.3 (C), 129.1 (CH), 129.1 (CH), 128.9 (CH), 128.9 (CH), 127.4 (CH), 125.7 (C), 125.2 (CH), 120.9 (CH), 109.4 (CH), 73.9 (C), 60.3 (d, *J*_{C-P} = 21.7 Hz, CH), 52.9 (d, *J*_{C-P} = 5.6 Hz, CH₃), 52.6 (d, *J*_{C-P} = 5.3 Hz, CH₃), 27.7 (CH₂), 15.5 (CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 10.35 (s, 1H), 8.97 (s, 1H), 7.08-7.02 (m, 3H), 6.88 (d, *J* = 7.2 Hz, 2H), 6.70 (d, *J* = 7.6 Hz, 1H), 6.54 (t, *J* = 7.4 Hz, 1H), 6.23 (d, *J* = 7.2 Hz, 1H), 4.49 (s, 1H), 3.63 (d, *J* = 11.2 Hz, 3H), 3.54 (d, *J* = 11.2 Hz, 3H), 2.53 (q, *J* = 6.8 Hz, 2H), 1.21 (t, *J* = 7.4 Hz, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 10.83. **HRMS** for C₂₀H₂₃N₃O₄P⁺: calcd. [M+H]⁺: 400.1421. found: 400.1432.

Dimethyl(4'-(4-bromophenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3e)




Following the general procedure, treatment of (4-Bromobenzylidene)indolin-2-one (50 mg, 0.17 mmol) with BOR (48 mg, 0.25 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3e** as a white solid (69 mg, 90%, 7:1 dr). **R_f** (Acetone/Dichloromethane : 3/7) = 0.42. **Mp** 174-

178 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 177.7 (C), 142.4 (C), 141.1 (d, *J*_{C-P} = 227.5 Hz, C), 133.7 (C), 131.1 (CH), 131.1 (CH), 131.0 (CH), 131.0 (CH), 129.3 (C), 125.5 (CH), 124.4 (C), 121.0 (CH), 120.8 (CH), 109.6 (CH), 73.6 (d, *J*_{C-P} = 4.7 Hz, C), 59.5 (d, *J*_{C-P} = 21.8 Hz, CH), 52.9 (d, *J*_{C-P} = 5.8 Hz, CH₃), 52.7 (d, *J*_{C-P} = 5.5 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 10.39 (s, 1H), 9.05 (s, 1H), 7.44 (d, *J* = 8.0 Hz, 2H), 7.07 (t, *J* = 7.8 Hz, 1H), 6.95 (d, *J* = 8.4 Hz, 2H), 6.72 (d, *J* = 8.0 Hz, 1H), 6.61 (t, *J* = 7.6 Hz, 1H), 6.28 (d, *J* = 7.2 Hz, 1H), 4.57 (s, 1H), 3.65 (d, *J* = 11.2 Hz, 3H), 3.57 (d, *J* = 11.2 Hz, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 10.54. **HRMS** for C₁₈H₁₈N₃O₄PBr⁺: calcd. [M+H]⁺: 450.1213, found: 450.1214.


Dimethyl (4'-(4-chlorophenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3f)

Following the general procedure, treatment of (4-Chlorobenzylidene)indolin-2-one (50 mg, 0.20 mmol) with BOR (57 mg, 0.30 mmol) in the presence of KOH (22 mg, 0.40 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3f**




as a white solid (75 mg, 94%, 5:1 dr). **R_f** (Acetone/Dichloromethane : 3/7) = 0.42. **Mp** 178-180 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 177.8 (C), 142.4 (C), 142.2 (d, J_{C-P} = 227.6 Hz, C), 133.3 (C), 132.2 (C), 130.8 (CH), 130.8 (CH), 129.3 (C), 128.1 (CH), 128.1 (CH), 125.5 (CH), 124.9 (CH), 121.0 (CH), 109.6 (CH), 73.7 (d, J_{C-P} = 4.6 Hz, C), 59.4 (d, J_{C-P} = 21.7 Hz, CH), 52.9 (d, J_{C-P} = 5.7 Hz, CH₃), 52.7 (d, J_{C-P} = 5.5 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 10.40 (s, 1H), 9.06 (s, 1H), 7.31 (d, J = 7.6 Hz, 2H), 7.08 (t, J = 7.8 Hz, 1H), 7.02 (d, J = 8.0 Hz, 2H), 6.73 (d, J = 8.0 Hz, 1H), 6.61 (t, J = 7.6 Hz, 1H), 6.27 (d, J = 7.2 Hz, 1H), 4.59 (s, 1H), 3.65 (d, J = 11.2 Hz, 3H), 3.57 (d, J = 11.2 Hz, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 10.58. **HRMS** for $C_{18}H_{18}N_3O_4P^{+}$: calcd. $[M+H]^{+}$: 406.0718, found: 406.0725.

Dimethyl (4'-(4-fluorophenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3g)



Following the general procedure, treatment of (4-fluorobenzylidene)indolin-2-one (50 mg, 0.21 mmol) with BOR (60 mg, 0.32 mmol) in the presence of KOH (23 mg, 0.42 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3g** as a pale yellow solid (77 mg, 94%, 10:1 dr). **R_f** (Acetone/Dichloromethane : 3/7) = 0.39. **Mp** 168-170 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 177.8 (C), 161.3 (d, J_{C-F} = 242.3 Hz, C), 142.4 (C), 141.5 (d, J_{C-P} = 227.5 Hz, C), 131.0 (d, J_{C-F} = 8.3 Hz, CH), 130.4 (d, J_{C-F} = 2.8 Hz, CH), 129.2 (C), 125.6 (CH), 125.0 (CH), 121.0 (CH), 115.0 (CH), 114.8 (CH), 109.5 (CH), 73.7 (d, J_{C-P} = 5.0 Hz, C), 59.3 (d, J_{C-P} = 21.7 Hz, CH), 52.9 (d, J_{C-P} = 5.9 Hz, CH₃), 52.7 (d, J_{C-P} = 5.6 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 10.38 (s, 1H), 9.02 (s, 1H), 7.10-7.00 (m, 5H), 6.72 (d, J = 7.6 Hz, 1H), 6.60 (dt, J = 7.2 Hz, 1H), 6.22 (d, J = 7.2 Hz, 1H), 4.58 (s, 1H), 3.64 (d, J = 11.2 Hz, 3H), 3.57 (d, J = 11.2 Hz, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 10.66. **HRMS** for $C_{18}H_{18}N_3O_4P^{+}$: calcd. $[M+H]^{+}$: 390.1013, found: 390.1014.


Dimethyl (4'-(4-cyanophenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3h)



Following the general procedure, treatment of (4-cyanobenzylidene)indolin-2-one (50 mg, 0.20 mmol) with BOR (57 mg, 0.30 mmol) in the presence of KOH (22 mg, 0.40 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3h** as a white solid (75 mg, 94%, 9:1 dr). R_f (Acetone/Dichloromethane : 3/7) = 0.39. **Mp** 172-

174 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 177.5 (C), 142.5 (C), 140.6 (J_{C-P} = 228.1 Hz, C), 140.1(C), 132.0 (CH), 132.0 (CH), 130.0 (CH), 130.0 (CH), 129.4 (C), 125.4 (CH), 124.5 (CH) 121.0 (CH), 118.6 (CH), 110.4 (C), 109.7 (C), 73.7 (d, J_{C-P} = 4.5 Hz, C), 59.5 (d, J_{C-P} = 21.7 Hz, CH), 53.0 (d, J_{C-P} = 5.7 Hz, CH₃), 52.7 (d, J_{C-P} = 5.6 Hz, CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 10.44 (s, 1H), 9.13 (s, 1H), 7.73 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 7.07 (t, J = 7.6 Hz, 1H), 6.73 (d, J = 8.0 Hz, 1H), 6.59 (t, J = 7.6 Hz, 1H), 6.20 (d, J = 7.6 Hz, 1H), 4.71 (s, 1H), 3.67 (d, J = 11.2 Hz, 3H), 3.58 (d, J = 11.2 Hz, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 10.37. **HRMS** for $C_{19}H_{18}N_4O_4P^+$: calcd. $[M+H]^+$: 397.1055, found: 397.1062.

(4-(5'-(Dimethoxyphosphoryl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-4'-yl)phenyl)boronic acid (3i)




Following the general procedure, treatment of (4-((2-oxoindolin-3-ylidene)methyl)phenyl)boronic acid (50 mg, 0.19 mmol) with BOR (56 mg, 0.29 mmol) in the presence of KOH (21 mg, 0.38 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3i** as a pale yellow solid (53 mg, 67%, 7:1 dr). R_f (Acetone/Dichloromethane : 5/5) = 0.33. **Mp** 184-186 °C. ^{13}C

NMR (100 MHz, δ ppm/ DMSO- d_6): 177.9 (C), 142.2 (C), 141.5 (d, J_{C-P} = 227.4 Hz, C), 135.8 (C), 133.9 (CH), 133.9 (CH), 133.3 (C), 129.1 (C), 129.1 (CH), 128.0 (C), 125.6 (CH), 125.1 (CH), 120.9 (CH), 109.4 (CH), 73.8 (d, J_{C-P} = 4.7 Hz, C), 60.5 (d, J_{C-P} = 21.8 Hz, CH), 52.8 (d, J_{C-P} = 5.8 Hz, CH₃), 52.6 (d, J_{C-P} = 5.5 Hz, CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 10.37 (s, 1H), 9.00 (s, 1H), 7.98 (s, 2H), 7.64 (d, J = 7.2 Hz, 2H), 7.03(t, J = 7.6 Hz, 1H), 6.95 (d, J = 7.6 Hz, 2H),

6.70 (d, $J = 8.0$ Hz, 1H), 6.53 (t, $J = 7.4$ Hz, 1H), 6.26 (d, $J = 7.6$ Hz, 1H), 4.52 (s, 1H), 3.63 (d, $J = 11.2$ Hz, 3H), 3.53 (d, $J = 11.2$ Hz, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 10.74. HRMS for $\text{C}_{18}\text{H}_{20}\text{N}_3\text{O}_6\text{PB}^+$: calcd. $[\text{M}+\text{H}]^+$: 416.1177, found: 416.1187.

Dimethyl (4'-(2,4-difluorophenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3j)




Following the general procedure, treatment of (2,4-difluorobenzylidene)indolin-2-one (50 mg, 0.19 mmol) with BOR (56 mg, 0.29 mmol) in the presence of KOH (21 mg, 0.38 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3j** as a pale yellow solid (47 mg, 61%, 10:1 dr).

R_f (Acetone/Dichloromethane : 3/7) = 0.36. **Mp** 175-177 °C. ^{13}C

NMR (100 MHz, δ ppm/ DMSO- d_6): 177.6 (C), 158.1 (d, $J_{\text{C-F}} = 239.8$ Hz, C), 155.7 (d, $J_{\text{C-F}} = 240.6$ Hz, C), 142.4 (C), 137.7 (d, $J_{\text{C-P}} = 230.3$ Hz, C), 129.7 (C), 125.2 (CH), 124.8 (C), 123.7 (d, $J_{\text{C-F}} = 7.5$ Hz, CH), 123.6 (d, $J_{\text{C-F}} = 7.4$ Hz, C) 121.3 (CH), 116.8 (d, $J_{\text{C-F}} = 24.7$ Hz, CH), 116.6 (d, $J_{\text{C-F}} = 5.0$ Hz, CH), 116.4 (CH), 109.7 (CH), 73.1 (d, $J_{\text{C-P}} = 4.5$ Hz, C), 53.2 (d, $J_{\text{C-P}} = 6.0$ Hz, CH_3), 52.8 (d, $J_{\text{C-P}} = 5.9$ Hz, CH_3). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 10.49 (s, 1H), 9.23 (s, 1H), 7.13-7.02 (m, 3H), 6.96-6.93 (m, 1H), 6.76 (d, $J = 7.6$ Hz, 1H), 6.64 (t, $J = 7.4$ Hz, 1H), 6.36 (d, $J = 6.8$ Hz, 1H), 4.71 (s, 1H), 3.71 (d, $J = 11.2$ Hz, 3H), 3.63 (d, $J = 11.2$ Hz, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 10.25. HRMS for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_4\text{PF}_2^+$: calcd. $[\text{M}+\text{H}]^+$: 408.0919, found: 408.0928.

Dimethyl (4'-(2,6-dichlorophenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3k)




Following the general procedure, treatment of (2,6-dichlorobenzylidene)indolin-2-one (50 mg, 0.17 mmol) with BOR (50 mg, 0.26 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3k** as a white solid (52 mg, 69%, 4:1 dr). R_f (Acetone/Dichloromethane : 3/7) = 0.36.

Mp 204-206 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 178.0 (C), 142.8 (C), 137.2 (d, $J_{\text{C-P}} = 233.0$ Hz, C), 135.7 (C), 131.8 (C), 130.0 (C), 130.0 (C), 129.9 (CH), 129.6 (CH), 128.1 (CH),

125.4 (CH), 125.4 (CH), 121.4 (CH), 109.7 (CH), 72.6 (d, J_{C-P} = 4.6 Hz, C), 57.0 (d, J_{C-P} = 23.2 Hz, CH), 53.0 (d, J_{C-P} = 5.5 Hz, CH₃), 52.8 (d, J_{C-P} = 5.5 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 10.50 (s, 1H), 9.33 (s, 1H), 7.42 (d, J = 1.6 Hz, 1H), 7.24-7.20 (m, 2H), 7.08 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 7.2 Hz, 1H), 6.75 (d, J = 7.2 Hz, 1H), 6.67 (t, J = 7.6 Hz, 1H), 5.26 (s, 1H), 3.70 (d, J = 11.2 Hz, 3H), 3.62 (d, J = 11.2 Hz, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 10.03. **HRMS** for C₁₈H₁₇N₃O₄PCl₂⁺: calcd. [M+H]⁺: 440.0328, found: 440.0325.


Dimethyl (4'-(2,4-dimethylphenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3l)



Following the general procedure, treatment of (2,4-dimethylbenzylidene)indolin-2-one (50 mg, 0.21 mmol) with BOR (60 mg, 0.32 mmol) in the presence of KOH (23 mg, 0.42 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3l** as a white solid (72 mg, 89%, 16:1 dr). **R_f** (Acetone/Dichloromethane : 3/7) = 0.38. **Mp** 203-

205 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 178.1 (C), 142.3 (C), 141.7 (d, J_{C-P} = 227.1 Hz, C), 136.6 (C), 135.9 (C), 130.8 (C), 129.3 (CH), 129.2 (CH), 128.4 (CH), 126.2 (CH), 125.6 (CH), 125.1 (CH), 120.9 (CH), 109.3 (CH), 72.8 (d, J_{C-P} = 4.8 Hz, C), 56.4 (d, J_{C-P} = 21.7 Hz, CH), 52.9 (d, J_{C-P} = 5.9 Hz, CH₃), 52.6 (d, J_{C-P} = 5.5 Hz, CH₃), 20.5 (CH₃) 18.5 (CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 10.42 (s, 1H), 8.99 (s, 1H), 7.09-7.04 (m, 2H), 6.94 (d, J = 8.0 Hz, 2H), 6.80 (s, 1H), 6.74 (d, J = 7.6 Hz, 1H), 6.52 (t, J = 7.6 Hz, 1H), 6.04 (d, J = 7.6 Hz, 1H), 4.60 (s, 1H), 3.66 (d, J = 11.2 Hz, 3H), 3.58 (d, J = 11.2 Hz, 3H), 2.21 (s, 3H), 1.66 (s, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 10.71. **HRMS** for C₂₀H₂₃N₃O₄P⁺: calcd. [M+H]⁺: 400.1421, found: 400.1429.


Dimethyl (4'-(2-chlorophenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3m)



Following the general procedure, treatment of (2-Chlorobenzylidene)indolin-2-one (50 mg, 0.20 mmol) with BOR (57 mg, 0.30 mmol) in the presence of KOH (22 mg, 0.40 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3m** as a white solid (72 mg, 89%, >20:1 dr). **R_f**

(Acetone/Dichloromethane : 3/7) = 0.44. **Mp** 187-189 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 177.7 (C), 143.0 (C), 139.5 (d, J_{C-P} = 227.6 Hz, C), 133.5 (C), 131.9 (C), 130.2 (CH), 129.5 (CH), 129.4 (CH), 129.2 (CH), 127.0 (CH), 125.1 (CH), 124.7 (C), 120.9 (CH), 110.5 (CH), 72.7 (d, J_{C-P} = 4.4 Hz, C), 56.3 (d, J_{C-P} = 21.4 Hz, CH), 53.0 (d, J_{C-P} = 5.8 Hz, CH₃), 53.6 (d, J_{C-P} = 5.6 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 10.47 (s, 1H), 9.16 (s, 1H), 7.42 (t, J = 7.2 Hz, 1H), 7.29-7.20 (m, 3H), 7.08 (t, J = 8.0 Hz, 1H), 6.75 (d, J = 8.0 Hz, 1H), 6.51 (t, J = 7.4 Hz, 1H), 6.00 (d, J = 7.2 Hz, 1H), 4.87 (s, 1H), 3.70 (d, J = 11.2 Hz, 3H), 3.60 (d, J = 11.2 Hz, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 10.41. **HRMS** for C₁₈H₁₈N₃O₄PCl⁺: calcd. [M+H]⁺: 406.0718, found: 406.0725.


Dimethyl (4'-(3-methoxyphenyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate(3n)



Following the general procedure, treatment of (3-methoxybenzylidene)indolin-2-one (50 mg, 0.20 mmol) with BOR (57 mg, 0.30 mmol) in the presence of KOH (22 mg, 0.40 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3n** as a white solid (72 mg, 89%, 7:1 dr). **R_f** (Acetone/Dichloromethane : 3/7) = 0.41. **Mp** 176-178 °C. **¹³C NMR**

(100 MHz, δ ppm/DMSO-*d*₆): 177.9 (C), 158.9 (C), 142.3 (C), 141.3 (d, J_{C-P} = 227.0 Hz, C), 135.5 (C), 129.2 (C), 129.1 (CH), 125.8 (CH), 125.2 (C), 121.2 (CH), 121.0 (CH), 114.7 (CH), 113.1 (CH), 109.4 (CH), 74.0 (d, J_{C-P} = 4.7 Hz, C), 60.3 (d, J_{C-P} = 21.7 Hz, CH), 54.9 (CH₃), 52.9 (d, J_{C-P} = 5.8 Hz, CH₃), 52.7 (d, J_{C-P} = 5.5 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 10.38 (s, 1H), 9.0 (s, 1H), 7.16 (t, J = 8.0 Hz, 1H), 7.04 (t, J = 7.8 Hz, 1H), 6.78 (d, J = 10.0 Hz, 1H), 6.72 (d, J = 7.6 Hz, 1H), 6.60-6.54 (m, 3H), 6.31 (d, J = 7.6 Hz, 1H), 4.53 (s, 1H), 3.64 (s, 3H), 3.65 (d, J = 10.0 Hz, 3H), 3.56 (d, J = 11.2 Hz, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 10.76. **HRMS** for C₁₉H₂₁N₃O₅P⁺: calcd. [M+H]⁺: 402.1213, found: 402.1214.


Dimethyl (4'-(naphthalen-1-yl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3o)



Following the general procedure, treatment of (naphthalen-2-ylmethylene)indolin-2-one (50 mg, 0.18 mmol) with BOR (52 mg, 0.27 mmol) in the presence of KOH (20 mg, 0.36 mmol) in MeOH (3


mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3o** as a white solid (37mg, 48 %, 7:1 dr). R_f (Acetone/Dichloromethane : 3/7) = 0.45. **Mp** 188-190 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 178.2 (C), 142.1 (C), 140.5 (d, J_{C-P} = 230.3 Hz, C), 139.3(C), 133.2 (C), 131.3 (C), 129.9 (C), 129.0 (C), 128.4 (CH), 128.2 (CH), 126.9 (CH), 126.2 (CH), 125.3 (CH), 125.1 (CH), 124.8 (CH), 122.2 (CH), 120.6 (CH), 109.3 (CH), 73.3 (C), 55.4 (d, J_{C-P} = 21.7 Hz, CH), 53.0 (d, J_{C-P} = 5.9 Hz, CH₃), 52.7 (d, J_{C-P} = 5.5 Hz, CH₃). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 10.48 (s, 1H), 9.12 (s, 1H), 7.80 (t, J = 7.8 Hz, 2H), 7.57-7.48 (m, 2H), 7.35-7.26 (m, 3H), 6.81 (t, J = 7.6 Hz, 1H), 6.58 (d, J = 7.6 Hz, 1H), 6.23 (t, J = 7.4 Hz, 1H), 5.97 (d, J = 7.6 Hz, 1H), 5.31 (s, 1H), 3.70 (d, J = 11.2 Hz, 3H), 3.57 (d, J = 11.2 Hz, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 10.84. **HRMS** for $\text{C}_{22}\text{H}_{21}\text{N}_3\text{O}_4\text{P}^+$: calcd. $[\text{M}+\text{H}]^+$: 422.1264, found: 422.1268.

Dimethyl (2-oxo-4'-(thiophen-2-yl)-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3p)




Following the general procedure, treatment of (thiophene-2-ylmethylene)indolin-2-one (50 mg, 0.22 mmol) with BOR (63 mg, 0.33 mmol) in the presence of KOH (25 mg, 0.44 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3p** as a white solid (60 mg, 73%, 8.3:1 dr). R_f (Acetone/Dichloromethane : 3/7) = 0.50. **Mp** 180-182 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 177.5 (C), 142.2 (C), 142.8 (C), 140.5 (d, J_{C-P} = 228.9 Hz, C), 136.2 (C), 129.5 (C), 127.6 (CH), 126.8 (CH), 126.0 (CH), 125.1 (CH), 125.0 (CH), 121.2 (CH), 109.5 (CH) 74.0 (C), 55.2 (d, J_{C-P} = 21.8 Hz, CH), 52.9 (d, J_{C-P} = 5.9 Hz, CH₃), 52.7 (d, J_{C-P} = 5.7 Hz, CH₃). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 10.42 (s, 1H), 9.06 (s, 1H), 7.37 (d, J = 4.8 Hz, 1H), 7.11 (t, J = 7.4 Hz, 1H), 6.92 (t, J = 4.8 Hz, 1H), 6.79 (d, J = 2.8 Hz, 1H), 6.74 (d, J = 7.6 Hz, 1H), 6.66 (t, J = 7.4 Hz, 1H), 6.45 (d, J = 7.2 Hz, 1H), 4.84 (s, 1H), 3.66 (d, J = 11.6 Hz, 3H), 3.59 (d, J = 11.2 Hz, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 10.24. **HRMS** for $\text{C}_{16}\text{H}_{17}\text{N}_3\text{O}_4\text{PS}^+$: calcd. $[\text{M}+\text{H}]^+$: 378.0672, found: 378.0662.

Dimethyl (4'-(furan-2-yl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (3q)



Following the general procedure, treatment of (furan-2-methylene)indolin-2-one (50 mg, 0.24 mmol) with BOR (68 mg, 0.36 mmol) in the presence of KOH (27 mg, 0.48 mmol) in MeOH (3 mL) at 25 °C for 1.5 h followed by column chromatography afforded the product **3q** as a pale yellow solid (57 mg, 66%, 10:1 dr). R_f (Acetone/Dichloromethane : 3/7) = 0.39. **Mp** 176-178 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 177.4 (C), 147.8 (C), 142.8 (C), 142.2 (CH), 137.3 (d, J_{C-P} = 230.3 Hz, C), 129.5 (C), 125.7 (CH), 125.1 (CH), 121.4 (CH), 110.7 (CH), 109.6 (CH), 109.5 (CH), 73.3 (d, J_{C-P} = 4.5 Hz, C), 54.2 (d, J_{C-P} = 21.9 Hz, CH), 52.8 (d, J_{C-P} = 5.9 Hz, CH₃), 52.7 (d, J_{C-P} = 5.6 Hz, CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 10.44 (s, 1H), 9.08 (s, 1H), 7.50 (s, 1H), 7.13 (t, J = 7.6 Hz, 1H), 6.76-6.71 (m, 2H), 6.59 (d, J = 7.6 Hz, 1H), 6.30 (s, 1H), 6.19 (s, 1H), 4.69 (s, 1H), 3.63 (d, J = 11.2 Hz, 3H), 3.59 (d, J = 11.2 Hz, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 10.48. **HRMS** for $C_{16}H_{17}N_3O_5P^+$: calcd. $[M+H]^+$: 362.0900, found: 362.0909.


Dimethyl (4'-isopropyl-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (**3r**)



Following the general procedure, treatment of (2-methylpropylidene)indolin-2-one (50 mg, 0.26 mmol) with BOR (77 mg, 0.40 mmol) in the presence of KOH (29 mg, 0.52 mmol) in MeOH (3 mL) at 25 °C for 2 h followed by column chromatography afforded the product **3r** as a white solid (55 mg, 61%, >20:1 dr). R_f (Acetone/Dichloromethane : 3/7) = 0.45. **Mp** 139-141 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 178.2 (C), 142.0 (C), 140.4 (d, J_{C-P} = 226.7 Hz, C), 129.7 (CH), 126.6 (C), 125.5 (CH), 121.6 (CH), 110.0 (CH), 74.5 (d, J_{C-P} = 5.4 Hz, C), 61.6 (d, J_{C-P} = 22.7 Hz, CH), 53.2 (d, J_{C-P} = 6.3 Hz, CH₃), 52.7 (d, J_{C-P} = 5.8 Hz, CH₃), 27.0 (CH), 21.1 (CH₃), 19.6 (CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 10.44 (s, 1H), 8.76 (s, 1H), 7.28-7.22 (m, 2H), 6.98 (t, J = 7.2 Hz, 1H), 6.85 (d, J = 7.6 Hz, 1H), 3.74 (d, J = 11.2 Hz, 3H), 3.70 (d, J = 11.2 Hz, 3H), 3.25 (d, J = 5.2 Hz, 1H), 1.94-1.86 (m, 1H), 1.00 (d, J = 6.8 Hz, 3H), 0.75 (d, J = 6.8 Hz, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 12.41. **HRMS** for $C_{15}H_{21}N_3O_4P^+$: calcd. $[M+H]^+$: 338.1264, found: 338.1275.


Dimethyl (1-benzoyl-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (**5a**)

Following the general procedure, treatment of 3-(2-oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.20 mmol) with BOR (58 mg, 0.30 mmol) in the presence of KOH (23 mg, 0.40 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the




product **5a** as a white solid (63 mg, 80%). R_f (Acetone/Dichloromethane: 3/7) = 0.38. **Mp** 226-228 °C. $^{13}\text{C NMR}$ (100 MHz, δ ppm/DMSO- d_6): 191.0 (C), 143.7 (C), 143.5 (d, J_{C-P} = 224.6 Hz, C), 138.7 (d, J_{C-P} = 9.0 Hz, C), 136.9 (C), 135.2 (C), 134.3 (C), 131.1 (CH), 129.6 (CH), 129.6 (CH), 128.9 (CH), 128.9 (CH), 123.5 (CH), 123.3 (CH), 120.0 (d, J_{C-P} = 24.4 Hz, C), 116.3 (CH), 111.2 (CH), 53.2 (d, J_{C-P} = 5.7 Hz, CH₃), 53.1 (d, J_{C-P} = 5.7 Hz, CH₃). $^1\text{H NMR}$ (400 MHz, δ ppm/DMSO- d_6): 12.31 (s, 1H), 7.90 (d, J = 7.6 Hz, 2H), 7.70 (t, J = 7.2, 1H), 7.53 (d, J = 7.6 Hz, 3H), 7.40 (d, J = 8.4 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.10 (t, J = 7.6, 1H), 3.62 (d, J = 11.2 Hz, 6H). $^{31}\text{P NMR}$ (161.9 MHz, DMSO- d_6): 8.75. **HRMS** for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_5\text{P}^+$: calcd. $[\text{M}+\text{H}]^+$: 398.0900, found: 398.0899.

Dimethyl (1-benzoyl-9-methoxy-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (**5b**)




Following the general procedure, treatment of 5-methoxy-3-(2-oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.18 mmol) with BOR (58 mg, 0.27 mmol) in the presence of KOH (20 mg, 0.36 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5b** as a white solid (47 mg, 62%). R_f (Acetone/Dichloromethane: 3/7) = 0.27. **Mp** 216-218 °C. $^{13}\text{C NMR}$ (100 MHz, δ ppm/CF₃COOD): 194.4 (C), 156.8 (C), 146.7 (C), 145.3 (d, J_{C-P} = 224.6 Hz, C), 140.7 (d, J_{C-P} = 9.0 Hz, C), 136.8 (C), 136.0 (C), 130.7 (CH), 130.7 (CH), 129.6 (CH), 129.6 (CH), 128.0 (CH), 122.0 (CH), 118.8 (d, J_{C-P} = 24.4 Hz, C), 118.7 (CH), 112.1 (CH), 107.9 (CH), 55.2 (CH₃), 54.6 (d, J_{C-P} = 5.7 Hz, CH₃), 54.5 (d, J_{C-P} = 5.7 Hz, CH₃). $^1\text{H NMR}$ (400 MHz, δ ppm/CF₃COOD): 8.20 (d, J = 7.6 Hz, 2H), 7.91 (t, J = 7.6 Hz, 1H), 7.71 (t, J = 7.8 Hz, 1H), 7.58 (d, J = 9.2 Hz, 1H), 7.43 (dd, J = 9.2, 2.8 Hz, 1H), 7.10 (d, J = 2.4 Hz, 1H), 4.06 (d, J = 11.6 Hz, 6H), 3.66 (s, 3H). $^{31}\text{P NMR}$ (161.9 MHz, CF₃COOD): 8.08. **HRMS** for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_6\text{P}^+$: calcd. $[\text{M}+\text{H}]^+$: 428.1006, found: 428.1016.

Dimethyl**(1-benzoyl-9-methyl-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5c)**

Following the general procedure, treatment of 5-methyl-3-2(oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.19 mmol) with BOR (55 mg, 0.29 mmol) in the presence of KOH (21 mg, 0.38 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5c** as a light yellow solid (59 mg, 75%). R_f (Acetone/Dichloromethane : 3/7) = 0.41. **Mp**

210-212 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 191.0 (C), 143.7 (C), 143.7 (d, J_{C-P} = 224.7 Hz, C), 138.7 (d, J_{C-P} = 9.1 Hz, C), 137.1 (C), 134.2 (CH), 133.1 (C), 132.2 (C), 132.2 (C), 129.5 (CH), 129.5 (CH), 128.9 (CH), 128.9 (CH), 123.4 (CH), 120.0 (d, J_{C-P} = 24.3 Hz, C), 116.2 (CH), 111.0 (CH), 53.2 (d, J_{C-P} = 5.7 Hz, CH₃), 53.2 (d, J_{C-P} = 5.7, CH₃), 20.4 (CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.24 (s, 1H), 7.89 (d, J = 7.6 Hz, 2H), 7.70 (t, J = 7.4 Hz, 1H), 7.53 (t, J = 7.8 Hz, 2H), 7.35-7.27 (m, 2H), 7.00 (s, 1H), 3.63 (d, J = 11.2 Hz, 6H), 2.08 (s, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.80. **HRMS** for $C_{20}H_{19}N_3O_5P^+$: calcd. $[M+H]^+$: 412.1057, found: 412.1071.


Dimethyl**(1-benzoyl-9-bromo-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5d)**

Following the general procedure, treatment of 5-bromo-3-2(oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.15 mmol) with BOR (44 mg, 0.22 mmol) in the presence of KOH (17 mg, 0.20 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5d** as a white solid (62 mg, 86%). R_f (Acetone/Dichloromethane : 3/7) = 0.40. **Mp**

220-222 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 190.2 (C), 143.9 (d, J_{C-P} = 224.0 Hz, C), 143.7 (C), 138.9 (d, J_{C-P} = 9.0 Hz, C), 136.0 (C), 135.2 (C), 132.0 (CH), 132.0 (CH), 131.5 (CH), 131.5 (CH), 129.2 (C), 128.7 (C), 123.5 (CH), 123.4 (CH), 119.5 (d, J_{C-P} = 24.4 Hz, C), 116.3 (CH), 111.1 (CH), 53.3 (d, J_{C-P} = 5.9 Hz, CH₃), 53.2 (d, J_{C-P} = 5.9 Hz, CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.42 (s, 1H), 7.92-7.89 (m, 2H), 7.73-7.67 (m, 2H), 7.55 (t, J = 7.8 Hz, 2H), 7.34-7.31 (m, 2H), 3.62 (d, J = 9.6 Hz, 6H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.39. **HRMS** for $C_{19}H_{16}N_3O_5PBr^+$: calcd. $[M+H]^+$: 476.0005, found: 476.0006.

Dimethyl

(1-benzoyl-9-chloro-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (**5e**)




Following the general procedure, treatment of 5-chloro-3-(2-oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.18 mmol) with BOR (51 mg, 0.27 mmol) in the presence of KOH (20 mg, 0.36 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5e** as a white solid (67 mg, 87%). *R_f* (Acetone/Dichloromethane : 3/7) = 0.38. **Mp** 230-

232 °C. ¹³C NMR (100 MHz, δ ppm/DMSO-*d*₆): 191.9 (C), 143.8 (d, *J* = 224.6 Hz, C), 143.5 (C), 137.7 (d, *J*_{C-P} = 9.0 Hz, C), 136.9 (C), 134.5 (C), 134.2 (C), 131.0 (C), 129.5 (CH), 129.5 (CH), 129.0 (CH), 129.0 (CH), 126.8 (CH), 122.6 (CH), 120.5 (d, *J*_{C-P} = 24.4 Hz, C), 118.2 (CH), 112.6 (CH), 53.2 (d, *J*_{C-P} = 5.7 Hz, CH₃), 53.2 (d, *J*_{C-P} = 5.7 Hz, CH₃). ¹H NMR (400 MHz, δ ppm/DMSO-*d*₆): 12.44 (s, 1H), 7.90 (dd, *J* = 2.4 Hz, 2H), 7.72 (t, *J* = 7.4, 1H), 7.59-7.53 (m, 3H), 7.39 (d, *J* = 7.2 Hz, 1H), 7.19 (d, *J* = 2.4 Hz, 1H), 3.62 (d, *J* = 11.2 Hz, 6H). ³¹P NMR (161.9 MHz, DMSO-*d*₆): 8.44. **HRMS** for C₁₉H₁₆N₃O₅PCl⁺: calcd. [M+H]⁺: 432.0510, found: 432.0511.

Dimethyl

(1-benzoyl-9-fluoro-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (**5f**)




Following the general procedure, treatment of 5-fluoro-3-(2-oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.19 mmol) with BOR (44 mg, 0.28 mmol) in the presence of KOH (38 mg, 0.20 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5f** as a yellow solid (59 mg, 74%). *R_f* (Acetone/Dichloromethane : 3/7) = 0.31. **Mp** 228-230 °C.

¹³C NMR (100 MHz, δ ppm/ DMSO-*d*₆): 190.8 (C), 157.1 (d, *J*_{C-F} = 239.0 Hz, C), 143.7 (d, *J*_{C-P} = 224.0 Hz, C), 143.4 (C), 138.0 (d, *J*_{C-P} = 9.0 Hz, C), 136.9 (C), 134.5 (C), 132.1 (C), 129.6 (CH), 129.6 (CH), 129.0 (CH), 129.0 (CH), 120.6 (CH), 119.0 (d, *J*_{C-P} = 23.8 Hz, C), 118.5 (d, *J*_{C-F} = 8.4 Hz, CH), 112.1 (d, *J*_{C-F} = 8.4 Hz, CH), 109.0 (d, *J*_{C-F} = 25.4 Hz, CH), 53.2 (d, *J*_{C-P} = 2.9 Hz, CH₃), 53.2 (d, *J*_{C-P} = 2.9 Hz, CH₃). ¹H NMR (400 MHz, δ ppm/DMSO-*d*₆): 12.42 (s, 1H), 7.90 (d, *J* = 8.4 Hz, 2H), 7.72 (t, *J* = 7.2 Hz, 1H), 7.54 (t, *J* = 7.8 Hz, 2H), 7.41 (d, *J* = 5.6 Hz, 2H), 6.92 (d, *J* = 8.8

Hz, 1H) 3.62 (d, J = 9.6 Hz, 6H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.51. HRMS for $\text{C}_{19}\text{H}_{16}\text{N}_3\text{O}_5\text{P}^+$: calcd. $[\text{M}+\text{H}]^+$: 416.0806, found: 416.0805.


Dimethyl (1-benzoyl-9-nitro-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5g)



Following the general procedure, treatment of 5-nitro-3-2-(oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.17 mmol) with BOR (49 mg, 0.26 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5g** as a yellow solid (52 mg, 69%). R_f (Acetone/Dichloromethane : 3/7) = 0.29. **Mp** 236-

238 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 190.7 (C), 144.2 (d, $J_{\text{C-P}}$ = 224.6 Hz, C), 143.5 (C), 141.9 (C), 140.3 (C), 137.6 (d, $J_{\text{C-P}}$ = 9.0 Hz, C), 136.8 (C), 134.6 (C), 129.5 (CH), 129.5 (CH), 129.0 (CH), 129.0 (CH), 125.9 (CH), 120.9 (d, $J_{\text{C-P}}$ = 24.3 Hz, C), 119.5 (CH), 117.3 (CH), 111.4 (CH), 53.3 (d, $J_{\text{C-P}}$ = 5.7 Hz, CH_3), 53.2 (d, $J_{\text{C-P}}$ = 5.7 Hz, CH_3). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.86 (s, 1H), 8.35 (dd, J = 8.0, 4.0 Hz, 1H), 8.14 (d, J = 2.4 Hz, 1H), 7.94 (d, J = 8 Hz, 2H), 7.72 (d, J = 7.6 Hz, 1H), 7.57-7.52 (m, 3H), 3.64 (d, J = 11.2 Hz, 6H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.23. HRMS for $\text{C}_{19}\text{H}_{16}\text{N}_4\text{O}_7\text{P}^+$: calcd. $[\text{M}+\text{H}]^+$: 443.0751 found: 443.0756.

Dimethyl (1-(4-methoxybenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5h)




Following the general procedure, treatment of 3-(2-(4-methoxyphenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.18 mmol) with BOR (52 mg, 0.27 mmol) in the presence of KOH (20 mg, 0.36 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5h** as a white solid (54 mg, 71%). R_f (Acetone/Dichloromethane : 3/7)

= 0.34. **Mp** 210-212 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 189.1 (C), 164.1 (C), 143.9 (d, $J_{\text{C-P}}$ = 224.6 Hz, C), 143.8 (C), 138.2 (d, $J_{\text{C-P}}$ = 9.0 Hz, C), 135.1 (C), 132.1 (CH), 132.1 (CH), 131.0 (C), 130.0 (C), 123.5 (CH), 123.3 (CH), 120.2 (d, $J_{\text{C-P}}$ = 24.4 Hz, C), 116.2 (CH), 114.2 (CH), 114.2 (CH), 111.3 (CH), 55.6 (CH_3), 53.2 (d, $J_{\text{C-P}}$ = 5.7 Hz, CH_3), 53.2 (d, $J_{\text{C-P}}$ = 5.7 Hz, CH_3). ^1H

NMR (400 MHz, δ ppm/DMSO- d_6): 12.28 (s, 1H), 7.86 (d, J = 7.2 Hz, 2H), 7.53-7.49 (m, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 6.8 Hz, 1H), 7.09 (t, J = 7.2 Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 3.84 (s, 3H), 3.63 (d, J = 11.6 Hz, 6H). **^{31}P NMR** (161.9 MHz, DMSO- d_6): 13.65. **HRMS** for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_6\text{P}^+$: calcd. $[\text{M}+\text{H}]^+$: 428.1006, found: 428.0983.


Dimethyl (1-(4-methylbenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5i)



Following the general procedure, treatment of 3-(2-oxo-2-(p-tolyl)ethylidene)indolin-2-one (50 mg, 0.19 mmol) with BOR (55 mg, 0.29 mmol) in the presence of KOH (21 mg, 0.38 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5i** as a pale yellow solid (63 mg, 81%). R_f (Acetone/Dichloromethane : 3/7) = 0.40 **Mp**

216-218 °C. **^{13}C NMR** (100 MHz, δ ppm/ DMSO- d_6): 190.4 (C), 145.1 (C), 143.8 (C), 143.5 (d, $J_{\text{C-P}}$ = 179.5 Hz, C), 138.5 (d, $J_{\text{C-P}}$ = 7.2 Hz, C), 135.1 (C), 134.5 (C), 131.1 (C), 129.7 (CH), 129.7 (CH), 129.5 (CH), 129.5 (CH), 123.5 (CH), 123.4 (CH), 120.2 (d, $J_{\text{C-P}}$ = 19.6 Hz, C), 116.3 (CH), 111.2 (CH), 53.2 (d, $J_{\text{C-P}}$ = 5.7 Hz, CH_3), 53.2 (d, $J_{\text{C-P}}$ = 5.7 Hz, CH_3), 21.2 (CH_3). **^1H NMR** (400 MHz, δ ppm/DMSO- d_6): 12.29 (s, 1H), 7.79 (d, J = 7.6 Hz, 2H), 7.52-7.48 (m, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.0, 1.2 Hz, 1H), 7.09 (dt, J = 7.2, 0.8 Hz, 1H), 3.62 (d, J = 11.6 Hz, 6H), 2.38 (s, 3H). **^{31}P NMR** (161.9 MHz, DMSO- d_6): 8.82. **HRMS** for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_5\text{P}^+$: calcd. $[\text{M}+\text{H}]^+$: 412.1057, found: 412.1050.

Dimethyl (1-([1,1'-biphenyl]-4-carbonyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5j)




Following the general procedure, treatment of 3-(2-oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.15 mmol) with BOR (43 mg, 0.23 mmol) in the presence of KOH (17 mg, 0.30 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5j** as a white solid (34 mg, 49%). R_f (Acetone/Dichloromethane: 3/7) = 0.40. **Mp** 220-

222 °C. **^{13}C NMR** (100 MHz, δ ppm/DMSO- d_6): 190.5 (C), 145.6 (C), 143.8 (C), 143.5 (d, $J_{\text{C-P}}$ = 224.4 Hz, C), 138.6 (d, $J_{\text{C-P}}$ = 9.0 Hz, C), 135.8 (C), 135.2 (C), 131.1 (C), 130.3 (CH), 130.3 (CH),

129.0 (CH), 129.0 (CH), 129.0 (CH), 128.6 (C), 127.0 (CH), 127.0 (CH), 127.0 (CH), 127.0 (CH), 123.5 (CH), 123.4 (CH), 120.0 (d, J_{C-P} = 24.7 Hz, C), 116.3 (CH), 111.2 (CH), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃), 53.2 (d, J_{C-P} = 5.7 Hz, CH₃). ¹H NMR (400 MHz, δ ppm/DMSO-*d*₆): 12.32 (s, 1H), 7.98 (d, J = 8.4 Hz, 2H), 7.83 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H), 7.53-7.47 (m, 3H), 7.44-7.39 (m, 2H), 7.32 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 3.64 (d, J = 11.2 Hz, 6H). ³¹P NMR (161.9 MHz, DMSO-*d*₆): 8.75. HRMS for C₂₅H₂₁N₃O₅P⁺: calcd. [M+H]⁺: 474.1212, found: 474.1224.


Dimethyl (1-(4-bromobenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5k)



Following the general procedure, treatment of 3-(2-(4-bromophenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.15 mmol) with BOR (44 mg, 0.23 mmol) in the presence of KOH (17 mg, 0.13 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5k** as a white solid (45 mg, 62%). *R_f* (Acetone/Dichloromethane : 3/7)

= 0.42. *Mp* 210-212 °C. ¹³C NMR (100 MHz, δ ppm/ DMSO-*d*₆): 190.2 (C), 143.7 (C), 143.4 (d, J_{C-P} = 224.1 Hz, C), 138.7 (d, J_{C-P} = 9.0 Hz, C), 136.0 (C), 135.2 (CH), 132.0 (C), 131.4 (CH), 131.4 (CH), 131.2 (CH), 131.2 (CH), 128.7 (C), 123.5 (C), 123.4 (CH), 119.5 (d, J_{C-P} = 24.5 Hz, C), 116.3 (CH), 111.1 (CH), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃), 53.2 (d, J_{C-P} = 5.6 Hz, CH₃). ¹H NMR (400 MHz, δ ppm/DMSO-*d*₆): 12.33 (s, 1H), 7.83 (d, J = 8.2 Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.55-7.51 (m, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.28 (t, J = 4.0 Hz, 1H), 7.14-7.10 (m, 1H), 3.63 (d, J = 10.0 Hz, 6H). ³¹P NMR (161.9 MHz, DMSO-*d*₆): 8.62. HRMS for C₁₉H₁₆N₃O₅PBr⁺: calcd. [M+H]⁺: 476.0005, found: 476.0004.


Dimethyl (1-(4-fluorobenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5l)



Following the general procedure, treatment of 3-(2-(4-fluorophenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.19 mmol) with BOR (54 mg, 0.28 mmol) in the presence of KOH (21 mg, 0.38 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column


chromatography afforded the product **5l** as a white solid (58 mg, 74%). **R_f** (Acetone/Dichloromethane : 3/7) = 0.28. **Mp** 208-210 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 189.5 (C), 165.7 (d, J_{C-F} = 252.3 Hz, C), 143.7 (d, J_{C-P} = 224.3 Hz, C), 143.7 (C), 138.7 (d, J_{C-P} = 8.8 Hz, C), 135.2 (C), 133.8 (d, J_{C-F} = 2.5 Hz, CH), 132.7 (d, J_{C-F} = 9.8 Hz, CH), 132.7 (d, J_{C-F} = 9.8 Hz, CH), 131.2 (C), 123.5 (CH), 123.3 (CH), 119.7 (d, J_{C-P} = 24.3 Hz, C), 116.3 (CH), 116.2 (CH), 115.9 (CH), 111.2 (CH), 53.2 (d, J_{C-P} = 5.8 Hz, CH₃), 53.2 (d, J_{C-P} = 5.8 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 12.32 (s, 1H), 8.01-7.97 (m, 2H), 7.53 (t, J = 7.6 Hz, 1H), 7.41-7.33 (m, 3H), 7.28 (d, J = 8.0 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 3.63 (d, J = 11.2 Hz, 6H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.70. **HRMS** for C₁₉H₁₆N₃O₅PF⁺: calcd. [M+H]⁺: 416.0806, found: 416.0820.

Dimethyl (9-bromo-1-(4-methoxybenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5m)



Following the general procedure, treatment of 5-bromo-3-(2-(4-methoxyphenyl)2-oxo-ethylidene)indolin-2-one (50 mg, 0.14 mmol) with BOR (40 mg, 0.21 mmol) in the presence of KOH (16 mg, 0.28 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5m** as a white solid (54 mg, 76%). **R_f** (Acetone/Dichloromethane : 3/7) = 0.38. **Mp** 210-212 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 189.0 (C), 164.2 (C), 143.6 (d, J_{C-P} = 224.7 Hz, C), 143.5 (C), 137.2 (d, J_{C-P} = 9.0 Hz, C), 134.4 (C), 133.6 (C), 132.1 (CH), 132.1 (CH), 129.9 (C), 125.6 (C), 120.8 (d, J_{C-P} = 24.6 Hz, C), 118.4 (CH), 114.6 (CH), 114.3 (CH), 114.3 (CH), 113.2 (CH), 55.7 (CH₃), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 12.41 (s, 1H), 7.87 (d, J = 7.2 Hz, 2H), 7.70-7.68 (m, 1H), 7.34-7.31 (m, 2H), 7.06 (d, J = 8.8 Hz, 2H), 3.86 (s, 3H), 3.64 (d, J = 11.2 Hz, 6H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.61. **HRMS** for C₂₀H₁₈N₃O₆PBr⁺: calcd. [M+H]⁺: 506.0111, found: 506.0110.


Dimethyl (9-bromo-1-(4-bromobenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5n)



Following the general procedure, treatment of 5-bromo-3-(2-(4-bromophenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.13 mmol) with BOR (36 mg, 0.20 mmol) in the presence of KOH (15 mg, 0.26 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5n** as a yellow solid (52 mg, 72%). R_f (Acetone/Dichloromethane : 3/7) = 0.40.

Mp 208-210 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 190.1 (C), 143.8 (d, J_{C-P} = 224.0 Hz, C), 143.5 (C), 137.6 (d, J_{C-P} = 9.0 Hz, C), 136.1 (C), 134.6 (C), 133.8 (C), 132.1 (CH), 132.1 (CH), 131.4 (CH), 131.4 (CH), 128.9 (C), 125.6 (C), 119.2 (d, J_{C-P} = 24.5 Hz, C), 118.5 (CH), 114.6 (CH), 113.0 (CH), 53.3 (d, J_{C-P} = 5.8 Hz, CH₃), 53.2 (d, J_{C-P} = 5.6 Hz, CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.46 (s, 1H), 7.82 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 8.4 Hz, 2H), 7.71 (d, J = 8.8 Hz, 1H), 7.36 (s, 1H), 7.33 (d, J = 8.8 Hz, 1H), 3.63 (d, J = 10.0 Hz, 6H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.33. **HRMS** for $C_{19}H_{15}N_3O_5PBr_2^+$: calcd. $[M+H]^+$: 553.9111, found: 553.9094


Dimethyl (9-bromo-1-(4-chlorobenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5o)



Following the general procedure, treatment of 5-bromo-3-(2-(4-chlorophenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.14 mmol) with BOR (40 mg, 0.21 mmol) in the presence of KOH (16 mg, 0.28 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5o** as a pale yellow solid (47 mg, 66%). R_f (Acetone/Dichloromethane : 3/7) =

0.28. **Mp** 210-212 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 189.9 (C), 143.8 (d, J_{C-P} = 224.5 Hz, C), 143.5 (C), 139.5 (C), 137.9 (C), 135.8 (C), 134.6 (C), 133.8 (C), 131.4 (CH), 131.4 (CH), 129.2 (CH), 129.2 (CH), 125.6 (C), 120.5 (d, J_{C-P} = 24.1 Hz, C), 118.5 (CH), 114.6 (CH), 113.1 (CH), 53.3 (d, J_{C-P} = 5.8 Hz, CH₃), 53.3 (d, J_{C-P} = 5.6 Hz, CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.46 (s, 1H), 7.91 (d, J = 8.8 Hz, 2H), 7.71 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 8.8 Hz, 2H), 7.36-7.32 (m, 2H), 3.63 (d, J = 11.6 Hz, 6H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.58. **HRMS** for $C_{19}H_{15}N_3O_5PBrCl^+$: calcd. $[M+H]^+$: 509.9616, found: 509.9614.


Dimethyl (9-chloro-1-(4-methoxybenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5p)



Following the general procedure, treatment of 5-chloro-3-(2-(4-methoxyphenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.16 mmol) with BOR (46 mg, 0.24 mmol) in the presence of KOH (18 mg, 0.32 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5p** as a white solid (51 mg, 69%). R_f (Acetone/Dichloromethane :

3/7) = 0.34. **Mp** 202–204 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 189.0 (C), 164.2 (C), 143.6 (d, J_{C-P} = 224.7 Hz, C), 143.5 (C), 137.3 (d, J_{C-P} = 9.0 Hz, C), 134.1 (C), 132.1 (CH), 132.1 (CH), 130.8 (C), 129.9 (C), 126.9 (C), 122.5 (CH), 120.8 (d, J_{C-P} = 24.4 Hz, C), 118.2 (CH), 114.3 (CH), 114.3 (CH), 112.7 (CH), 55.7 (CH₃), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃), 53.2 (d, J_{C-P} = 5.7 Hz, CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.41 (s, 1H), 7.87 (d, J = 7.6 Hz, 2H), 7.56 (s, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.20 (s, 1H), 7.06 (d, J = 8.2 Hz, 2H), 3.86 (s, 3H), 3.63 (d, J = 10.0 Hz, 6H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.58. **HRMS** for $C_{20}H_{18}N_3O_6P^{+}$: calcd. $[M+H]^+$: 462.0616, found: 462.0616.

Dimethyl (9-chloro-1-(4-methylbenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5q)




Following the general procedure, treatment of 5-chloro-3-(2-oxo-2-(p-tolyl)ethylidene)indolin-2-one (50 mg, 0.17 mmol) with BOR (50 mg, 0.26 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5q** as a white solid (59 mg, 78%). R_f (Acetone/Dichloromethane : 3/7) = 0.42. **Mp** 220–

222 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 190.3 (C), 145.3 (C), 143.7 (d, J_{C-P} = 179.4 Hz, C), 143.5 (C), 137.5 (d, J_{C-P} = 7.2 Hz, C), 134.5 (C), 134.1 (C), 130.9 (C), 129.7 (CH), 129.7 (CH), 129.6 (CH), 129.6 (CH), 126.8 (C), 122.5 (CH), 120.7 (d, J_{C-P} = 19.6 Hz, C), 118.2 (CH), 112.7 (CH), 53.2 (CH₃), 53.2 (CH₃), 21.2 (CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.43 (s, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.57–7.55 (m, 1H), 7.39–7.34 (m, 3H), 7.18 (d, J = 2.4 Hz, 1H), 3.63 (d,

$J = 11.6$ Hz, 6H), 2.39 (s, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.50. HRMS for $\text{C}_{20}\text{H}_{18}\text{N}_3\text{O}_5\text{PCl}^+$: calcd. $[\text{M}+\text{H}]^+$: 446.0667, found: 446.0652.


Dimethyl (1-(4-bromobenzoyl)-9-chloro-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5r)



Following the general procedure, treatment of 3-(2-(4-bromophenyl)-2-oxoethylidene)-5-chloroindolin-2-one (50 mg, 0.14 mmol) with BOR (40 mg, 0.21 mmol) in the presence of KOH (16 mg, 0.28 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5r** as a white solid (47 mg, 66%). R_f (Acetone/Dichloromethane : 3/7)

= 0.40. **Mp** 204-206 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 190.1 (C), 143.7 (d, $J_{\text{C-P}} = 224.0$ Hz, C), 143.4 (C), 138.4 (d, $J_{\text{C-P}} = 9.0$ Hz, C), 136.1 (C), 134.2 (C), 132.1 (C), 131.4 (CH), 131.4 (CH), 131.1 (CH), 131.1 (CH), 128.9 (C), 126.9 (C), 122.6 (CH), 120.1 (d, $J_{\text{C-P}} = 24.5$ Hz, C), 118.3 (CH), 112.6 (CH), 53.3 (d, $J_{\text{C-P}} = 5.8$ Hz, CH_3), 53.3 (d, $J_{\text{C-P}} = 5.6$ Hz, CH_3). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.47 (s, 1H), 7.84-7.81 (m, 2H), 7.75 (d, $J = 8.4$ Hz, 2H), 7.59 (dd, $J = 8.8, 2.0$ Hz, 1H), 7.39 (d, $J = 8.8$ Hz, 1H), 7.23 (d, $J = 2.0$ Hz, 1H), 3.63 (d, $J = 11.6$ Hz, 6H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.31. HRMS for $\text{C}_{19}\text{H}_{15}\text{N}_3\text{O}_5\text{PClBr}^+$: calcd. $[\text{M}+\text{H}]^+$: 509.9616, found: 509.9609.

Dimethyl (9-chloro-1-(4-fluorobenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5s)




Following the general procedure, treatment of 5-chloro-3-(2-(4-fluorophenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.17 mmol) with BOR (50 mg, 0.26 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5s** as a white solid (54 mg, 71%). R_f (Acetone/Dichloromethane : 3/7) = 0.34.

Mp 211-213 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 189.9 (C), 166.2 (d, $J_{\text{C-F}} = 252.8$ Hz, C), 143.7 (d, $J_{\text{C-P}} = 224.3$ Hz, C), 143.5 (C), 137.6 (d, $J_{\text{C-P}} = 8.8$ Hz, C), 134.2 (C), 133.8 (C), 132.8 (d, $J_{\text{C-F}} = 24.3$ Hz, CH), 132.8 (d, $J_{\text{C-F}} = 2.5$ Hz, CH), 131.0 (C), 126.9 (CH), 122.6 (CH), 120.2 (d, $J_{\text{C-F}} = 24.3$ Hz, C), 118.3 (C), 116.1 (d, $J_{\text{C-F}} = 22.1$ Hz, CH), 116.1 (d, $J_{\text{C-F}} = 22.1$ Hz, CH), 112.6


(CH), 53.3 (d, J_{C-P} = 5.9 Hz, CH₃), 53.2 (d, J_{C-P} = 5.9 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 12.46 (s, 1H), 8.01-7.97 (m, 2H), 7.61-7.59 (m, 1H), 7.39 (d, J = 9.0 Hz, 3H), 7.22 (d, J = 2.0 Hz, 1H), 3.63 (d, J = 11.2 Hz, 6H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.38. **HRMS** for C₁₉H₁₅N₃O₅PClF⁺: calcd. [M+H]⁺: 450.0416, found: 450.0415.

Dimethyl (9-methoxy-1-(4-methoxybenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-*c*]quinazolin-2-yl)phosphonate (5t)



Following the general procedure, treatment of 5-methoxy-3-(2-(4-methoxyphenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.16 mmol) with BOR (46 mg, 0.24 mmol) in the presence of KOH (18 mg, 0.32 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5t** as a white solid (40 mg, 55%) **R_f** (Acetone/Dichloromethane : 3/7) = 0.26. **Mp** 216-218 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 188.9 (C), 164.1 (C), 154.6 (C), 143.5 (C), 143.1 (d, J_{C-P} = 224.6 Hz, C), 138.1 (d, J_{C-P} = 9.0 Hz, C), 132.0 (C), 130.0 (CH), 130.0 (CH), 129.1 (C), 120.4 (d, J_{C-P} = 24.4 Hz, C), 118.9 (C), 117.6 (CH), 114.3 (CH), 114.3 (CH), 114.3 (CH), 106.6 (CH), 55.6 (CH₃), 55.0 (CH₃), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 12.19 (s, 1H), 7.88 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 8.8 Hz, 2H), 7.15 (dd, J = 2.8, 9.2 Hz, 1H), 7.05 (d, J = 8.8 Hz, 2H), 6.65 (d, J = 2.8 Hz, 1H), 3.84 (s, 3H), 3.66 (d, J = 11.2 Hz, 6H), 3.39 (s, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.95. **HRMS** for C₂₁H₂₁N₃O₇P⁺: calcd. [M+H]⁺: 458.1112, found: 458.1112.


Dimethyl (1-(4-bromobenzoyl)-9-methoxy-5-oxo-5,6-dihydropyrazolo[1,5-*c*]quinazolin-2-yl)phosphonate (5u)



Following the general procedure, treatment of 3-(2-(4-bromophenyl)-2-oxoethylidene)-5-methoxyindolin-2-one (50 mg, 0.14 mmol) with BOR (40 mg, 0.21 mmol) in the presence of KOH (16 mg, 0.28 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5t** as a white solid (36 mg, 51%). **R_f** (Acetone/Dichloromethane : 3/7) = 0.36. **Mp** 235-237 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 189.9 (C), 154.6 (C), 143.7 (d, J_{C-P} = 224.7 Hz, C), 143.5 (C), 138.7 (d, J_{C-P} = 9.0 Hz, C), 136.1 (C), 132.2 (CH), 132.2 (CH),

131.4 (CH), 131.4 (CH), 129.2 (C), 128.7 (C), 119.6 (d, J_{C-P} = 24.4 Hz, C), 119.2 (C), 117.7 (CH), 111.5 (CH), 106.6 (CH), 55.1 (CH₃), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃), 53.3 (d, J_{C-P} = 5.7 Hz, CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 12.22 (s, 1H), 7.84 (d, J = 8.4 Hz, 2H), 7.76 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.8 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 6.63 (s, 1H), 3.66 (d, J = 11.2 Hz, 6H), 3.43 (s, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.67. **HRMS** for C₂₀H₁₈N₃O₆PBr⁺: calcd. [M+H]⁺: 506.0111, found: 506.0112.


Dimethyl (9-methyl-1-(4-methylbenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5v)



Following the general procedure, treatment of 5-methyl-3-(2-oxo-2-(p-tolyl)ethylidene)indolin-2-one (50 mg, 0.18 mmol) with BOR (52 mg, 0.27 mmol) in the presence of KOH (20 mg, 0.36 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5v** as a light yellow solid (40 mg, 53%). **R_f** (Acetone/Dichloromethane : 3/7) = 0.47. **Mp**

214-216°C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 190.5 (C), 144.9 (C) 143.7 (d, J_{C-P} = 224.7 Hz, C), 143.7 (C), 138.4 (d, J_{C-P} = 9.1 Hz, C), 134.7 (C), 133.0 (C), 132.3 (C), 132.1 (C), 129.6 (CH), 129.6 (CH), 129.5 (CH), 129.5 (CH), 123.3 (CH), 120.1 (d, J_{C-P} = 24.3 Hz, C), 116.2 (CH), 111.1 (CH), 53.2 (d, J_{C-P} = 5.7 Hz, CH₃), 53.1 (d, J_{C-P} = 5.7, CH₃), 21.2 (CH₃), 20.4 (CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 12.22 (s, 1H), 7.78 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 3H), 7.28 (d, J = 8.4 Hz, 1H), 7.01 (s, 1H), 3.63 (d, J = 11.2 Hz, 6H), 2.38 (s, 3H), 2.08 (s, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.85. **HRMS** for C₂₁H₂₁N₃O₅P⁺: calcd. [M+H]⁺: 426.1213 found: 426.1239


Dimethyl (9-fluoro-1-(4-methylbenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5w)



Following the general procedure, treatment of 5-fluoro-3-(2-oxo-2-(p-tolyl)ethylidene)indolin-2-one (50 mg, 0.18 mmol) with BOR (56 mg, 0.27 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5w** as a white solid (60

mg, 78%). **R_f** (Acetone/Dichloromethane : 3/7) = 0.40. **Mp** 220-222 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 190.3 (C), 157.1 (d, *J*_{C-F} = 238.9 Hz, C), 145.3 (C), 143.6 (d, *J*_{C-P} = 224.0 Hz, C), 143.5 (C), 137.6 (d, *J*_{C-P} = 9.0 Hz, C), 134.5 (C), 132.0 (C), 129.7 (CH), 129.7 (CH), 129.6 (CH), 129.6 (CH), 120.7 (d, *J*_{C-P} = 23.8 Hz, C), 119.0 (d, *J*_{C-F} = 9.0 Hz, C), 118.5 (d, *J*_{C-F} = 8.3 Hz, CH), 112.1 (d, *J*_{C-F} = 9.0 Hz, CH), 109.0 (d, *J*_{C-F} = 25.6 Hz, CH), 53.3 (d, *J*_{C-P} = 5.7 Hz, CH₃), 53.2 (d, *J*_{C-P} = 5.7, CH₃), 21.2 (CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 12.36 (s, 1H), 7.80 (d, *J* = 8.0 Hz, 2H), 7.41 (d, *J* = 5.6 Hz, 2H), 7.34 (d, *J* = 8.4 Hz, 2H), 6.91 (d, *J* = 7.8 Hz, 1H), 3.62 (d, *J* = 11.2 Hz, 6H), 2.39 (s, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.56. **HRMS** for C₂₀H₁₈N₃O₅PF⁺: calcd. [M+H]⁺: 430.0963 found: 430.0961.

Dimethyl (9-methoxy-1-(4-methylbenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5x)




Following the general procedure, treatment of 5-methoxy-3-(2-oxo-2-(p-tolyl)ethylidene)indolin-2-one (50 mg, 0.17 mmol) with BOR (49 mg, 0.26 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5x** as a white solid (44 mg, 60%). **R_f** (Acetone/Dichloromethane : 3/7) =

0.23. **Mp** 238-240 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 190.1 (C), 154.6 (C), 145.2 (C), 143.7 (d, *J*_{C-P} = 224.2 Hz, C), 143.5 (C), 138.4 (d, *J*_{C-P} = 8.8 Hz, C), 134.6 (C), 129.6 (CH), 129.6 (CH), 129.6 (CH), 129.1 (CH), 120.3 (d, *J*_{C-P} = 24.4 Hz, C), 119.0 (C), 117.7 (CH), 111.6 (CH), 106.6 (CH), 55.0 (CH₃), 53.3 (d, *J*_{C-P} = 5.7 Hz, CH₃), 53.2 (d, *J*_{C-P} = 5.7 Hz, CH₃), 21.2 (CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 12.18 (s, 1H), 7.81 (d, *J* = 7.2 Hz, 2H), 7.35-7.30 (m, 3H), 7.14 (d, *J* = 8.8 Hz, 1H), 6.62 (s, 1H), 3.65 (d, *J* = 11.2 Hz, 6H), 3.37 (s, 3H), 2.38 (s, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.88. **HRMS** for C₂₁H₂₁N₃O₆P⁺: calcd. [M+H]⁺: 442.1162, found: 442.1159.


Dimethyl (1-benzoyl-7,9-dimethyl-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5y)

Following the general procedure, treatment of 5,7-dimethyl-3-(2-oxo-2-phenylethylidene)indolin-2-one (50 mg, 0.18 mmol) with BOR (52 mg, 0.27 mmol) in the presence of KOH (20 mg, 0.36 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column



chromatography afforded the product **5y** as a white solid (44 mg, 58%). **R_f** (Acetone/Dichloromethane : 3/7) = 0.34. **Mp** 226-228 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 191.0 (C), 144.0 (C), 143.9 (d, *J*_{C-P} = 224.7 Hz, C), 138.7 (d, *J*_{C-P} = 9.1 Hz, C), 137.1 (C), 134.2 (C), 133.5 (C), 132.0 (C), 131.4 (CH), 129.5 (CH), 129.5 (CH), 128.9 (CH), 128.9 (CH), 125.0 (CH), 121.4 (C), 120.0 (d, *J*_{C-P} = 24.3 Hz, C), 111.1 (CH), 53.2 (d, *J*_{C-P} = 5.7 Hz, CH₃), 53.2 (d, *J*_{C-P} = 5.7, CH₃), 20.1 (CH₃), 17.6 (CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 11.36 (s, 1H), 7.88 (d, *J* = 7.6 Hz, 2H), 7.69 (t, *J* = 7.2 Hz, 1H), 7.52 (t, *J* = 7.6 Hz, 2H), 7.16 (s, 1H), 6.86 (s, 1H), 3.63 (d, *J* = 11.2 Hz, 6H), 2.40 (s, 3H), 2.01 (s, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.78. **HRMS** for C₂₁H₂₁N₃O₅P⁺: calcd. [M+H]⁺: 426.1213 found: 426.1249.


Dimethyl (7,9-dimethyl-1-(4-methylbenzoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (**5z**)



Following the general procedure, treatment of 5,7-dimethyl-3-(2-oxo-2-(p-tolyl)ethylidene)indolin-2-one (50 mg, 0.17 mmol) with BOR (50 mg, 0.26 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5z** as a white solid (49 mg, 66%). **R_f** (Acetone/Dichloromethane : 3/7) = 0.31. **Mp** 240-

242 °C. **¹³C NMR** (100 MHz, δ ppm/ DMSO-*d*₆): 190.5 (C), 144.9 (C), 144.0 (C), 143.7 (d, *J*_{C-P} = 224.7 Hz, C), 138.6 (d, *J*_{C-P} = 9.1 Hz, C), 134.7 (C), 133.5 (C), 132.0 (C), 131.4 (C), 129.6 (CH), 129.6 (CH), 129.5 (CH), 129.5 (CH), 125.0 (CH), 121.3 (C), 120.0 (d, *J*_{C-P} = 24.3 Hz, C), 111.1 (CH), 53.2 (d, *J*_{C-P} = 5.7 Hz, CH₃), 53.2 (d, *J*_{C-P} = 5.7, CH₃), 21.2 (CH₃), 20.2 (CH₃), 17.6 (CH₃). **¹H NMR** (400 MHz, δ ppm/DMSO-*d*₆): 11.34 (s, 1H), 7.78 (d, *J* = 8.0 Hz, 2H), 7.32 (d, *J* = 7.6 Hz, 2H), 7.18 (d, *J* = 5.2 Hz, 1H), 6.88 (s, 1H), 3.63 (d, *J* = 11.2 Hz, 6H), 2.41 (s, 3H), 2.38 (s, 3H), 2.03 (s, 3H). **³¹P NMR** (161.9 MHz, DMSO-*d*₆): 8.82. **HRMS** for C₂₂H₂₃N₃O₅P⁺: calcd. [M+H]⁺: 440.1370 found: 440.1377.


Dimethyl (1-(1-naphthoyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5aa)



Following the general procedure, treatment of (2-(naphthalen-1-yl)-2-oxoethylidene)indolin-2-one (50 mg, 0.17 mmol) with BOR (50 mg, 0.26 mmol) in the presence of KOH (19 mg, 0.34 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5aa** as a white solid (42 mg, 56%). R_f (Acetone/Dichloromethane : 2/8) = 0.36. **Mp** 200-

202 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 191.1 (C), 144.0 (C), 143.8 (d, J_{C-P} = 224.1 Hz, C), 139.1 (d, J_{C-P} = 8.9 Hz, C), 135.7 (C), 135.4 (C), 134.7 (C), 133.3 (C), 132.3 (C), 131.3 (CH), 129.9 (CH), 129.5 (CH), 128.9 (CH), 127.9 (CH), 127.3 (CH), 123.9 (CH), 123.8 (CH), 123.6 (CH), 120.4 (d, J_{C-P} = 24.4 Hz, C), 116.5 (CH), 111.5 (CH), 53.4 (d, J_{C-P} = 5.7 Hz, CH₃), 53.4 (d, J_{C-P} = 5.7, CH₃). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.34 (s, 1H), 8.44 (s, 1H), 8.08 (d, J = 0.8 Hz, 2H), 8.03-7.97 (m, 2H), 7.68 (dt, J = 8.0, 1.2 Hz, 1H), 7.57 (dt, J = 8.0, 0.8 Hz, 1H), 7.48 (dt, J = 8.4, 1.2 Hz, 1H), 7.39 (d, J = 5.2 Hz, 1H), 7.33 (dd, J = 8.0, 1.2 Hz, 1H), 7.07 (dt, J = 8.0, 1.2 Hz, 1H), 3.59 (d, J = 11.2 Hz, 6H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 8.76. **HRMS** for C₂₃H₁₉N₃O₅P⁺: calcd. [M+H]⁺: 448.1057 found: 448.1066.


Dimethyl (1-acetyl-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5ab)



Following the general procedure, treatment of 2-oxopropylidene)indolin-2-one (50 mg, 0.27 mmol) with BOR (77 mg, 0.40 mmol) in the presence of KOH (30 mg, 0.54 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5ab** as a yellow solid (40 mg, 44%). R_f (Acetone/Dichloromethane : 2/8) = 0.30. **Mp** 186-188 °C. ^{13}C NMR

(100 MHz, δ ppm/ DMSO- d_6): 198.5 (C), 143.9 (C), 143.3 (d, J_{C-P} = 222.0 Hz, C), 139.0 (d, J_{C-P} = 9.1 Hz, C), 135.7 (C), 132.1 (C), 124.7 (CH), 123.8 (CH), 123.6 (d, J_{C-P} = 24.6 Hz, C), 116.7 (CH), 111.8 (CH), 54.2 (d, J_{C-P} = 6.0 Hz, CH₃), 54.2 (d, J_{C-P} = 6.0 Hz, CH₃), 33.1 (CH₃). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.32 (s, 1H), 7.94 (d, J = 8 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.38 (d, J = 8.0, 1H), 7.29 (t, J = 7.6, 1H), 3.81 (d, J = 11.2 Hz, 6H), 2.72 (s, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 9.46. **HRMS** for C₁₄H₁₅N₃O₅P⁺: calcd. [M+H]⁺: 336.0744 found: 336.0743.


Dimethyl (1-acetyl-9-bromo-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5ac)



Following the general procedure, treatment of 5-bromo-3-(2-oxopropylidene)indolin-2-one (50 mg, 0.19 mmol) with BOR (55 mg, 0.28 mmol) in the presence of KOH (21 mg, 0.38 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5ac** as a white solid (35 mg, 45%). R_f (Acetone/Dichloromethane : 2/8) = 0.33. **Mp** 174-

176 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 198.2 (C), 143.9 (d, J_{C-P} = 222.0 Hz, C), 143.7 (C), 138.4 (d, J_{C-P} = 9.1 Hz, C), 135.1 (C), 134.7 (C), 127.0 (C), 123.7 (d, J_{C-P} = 24.7 Hz, C), 118.7 (CH), 115.2 (CH), 113.7 (CH), 54.3 (d, J_{C-P} = 6.1 Hz, CH₃), 54.2 (d, J_{C-P} = 6.1 Hz CH₃), 33.0 (CH₃). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.45 (s, 1H), 8.23 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 3.83 (d, J = 11.2 Hz, 6H), 2.76 (s, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 9.34. **HRMS** for C₁₄H₁₄BrN₃O₅P⁺: calcd. [M+H]⁺: 413.9849 found: 413.9854.


Dimethyl (1-acetyl-9-bromo-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (5ad)




Following the general procedure, treatment of 5-methyl-3-(2-oxopropylidene)indolin-2-one (50 mg, 0.25 mmol) with BOR (72 mg, 0.37 mmol) in the presence of KOH (28 mg, 0.50 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **5ad** as a light yellow solid (45 mg, 52%). R_f (Acetone/Dichloromethane : 2/8) = 0.33. **Mp**

180-182 °C. ^{13}C NMR (100 MHz, δ ppm/ DMSO- d_6): 198.5 (C), 143.3 (d, J_{C-P} = 222.0 Hz, C), 143.9 (C), 138.9 (d, J_{C-P} = 8.8 Hz, C), 133.5 (C), 133.1 (C), 132.9 (C), 124.2 (C), 123.3 (d, J_{C-P} = 24.7 Hz, C), 116.6 (CH), 111.6 (CH), 54.2 (d, J_{C-P} = 5.9 Hz, CH₃), 54.2 (d, J_{C-P} = 5.9 Hz, CH₃), 33.0 (CH₃), 21.1 (CH₃). ^1H NMR (400 MHz, δ ppm/DMSO- d_6): 12.25 (s, 1H), 7.71 (s, 1H), 7.40 (s, 1H), 7.29 (s, 1H), 3.82 (d, J = 11.2 Hz, 6H), 2.73 (s, 3H), 2.34 (s, 3H). ^{31}P NMR (161.9 MHz, DMSO- d_6): 9.51. **HRMS** for C₁₅H₁₇N₃O₅P⁺: calcd. [M+H]⁺: 350.0900 found: 350.0912.

Procedure for the one- pot, cycloaddition-click reaction sequence for the synthesis of compound 7




Dimethyl (1-benzoyl-6-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)-5-oxo-5,6-dihydropyrazolo[1,5-c]quinazolin-2-yl)phosphonate (7)





To an oven-dried round bottom flask was added N-propargyl-3-phenacylideneoxindole **6** (50 mg, 0.18 mmol) and dissolved in 3 mL of MeOH. Subsequently, a solution of Bestmann-Ohira reagent (52 mg, 0.27 mmol) in 2 mL of MeOH was added to the reaction mixture and kept stirring. After addition of potassium hydroxide (20 mg, 0.36 mmol), the reaction mixture was further stirred at 25 °C for 1.5 h. After the completion of reaction, as indicated by TLC, the requisite amount of CuSO_4 (6 mg, 0.02 mmol), sodium ascorbate (10 mg, 0.048 mmol) and BnN_3 (18 mg, 0.14 mmol) were added and kept for an additional stirring of 2 h. Subsequently, solvent was evaporated off and crude reaction mixture was extracted using ethyl acetate. The organic layer was dried over anhydrous Na_2SO_4 and solvent was evaporated under reduced pressure. Column chromatographic purification carried out using 100-200 mesh silica gel using dichloromethane-acetone as eluent afforded the product (62 mg) in 71% yield. R_f (Acetone/Dichloromethane: 2/8) = 0.33. **Mp** 160-162 °C. ^{13}C NMR (100 MHz, δ ppm/ CDCl_3): 191.2 (C), 146.2 (d, $J_{\text{C-P}}$ = 224.6 Hz, C), 145.1 (C), 142.5 (C), 138.2 (d, $J_{\text{C-P}}$ = 9.0 Hz, C), 137.3 (C), 135.2 (C), 134.4 (C), 134.1 (C), 131.9 (CH), 129.9 (CH), 129.9 (CH), 129.2 (CH), 129.2 (CH), 129.0 (CH), 128.9 (CH), 128.9 (CH), 128.4 (CH), 128.4 (CH), 125.4 (CH), 124.4 (CH), 123.9 (C), 120.9 (d, $J_{\text{C-P}}$ = 24.1 Hz, C), 116.3 (CH), 112.4 (CH), 54.5 (CH_2), 53.6 (d, $J_{\text{C-P}}$ = 5.7 Hz, CH_3), 53.6 (d, $J_{\text{C-P}}$ = 5.7 Hz, CH_3), 40.2 (CH_2). ^1H NMR (400 MHz, δ ppm/ CDCl_3): 8.03 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 7.6 Hz, 2H), 7.72 (s, 1H), 7.60-7.53 (m, 3H), 7.45 (t, J = 7.4 Hz, 2H), 7.34-7.26 (m, 5H), 7.11 (t, J = 7.6 Hz, 1H), 5.60 (s, 2H), 5.46 (s, 2H), 3.72 (d, J = 11.2 Hz, 6H). ^{31}P NMR (161.9 MHz, CDCl_3): 8.75. **HRMS** for $\text{C}_{29}\text{H}_{26}\text{N}_6\text{O}_5\text{P}^+$: calcd. $[\text{M}+\text{H}]^+$: 569.1697, found: 569.1699.



Dimethyl (4'-(4-fluorobenzoyl)-2-oxo-2',4'-dihydrospiro[indoline-3,3'-pyrazol]-5'-yl)phosphonate (8)







Following the general procedure, treatment of (2-(4-fluorophenyl)-2-oxoethylidene)indolin-2-one (50 mg, 0.19 mmol) with BOR (54 mg, 0.28 mmol) in the presence of KOH (21 mg, 0.38 mmol) in MeOH (3 mL) at 25 °C for 1 h followed by column chromatography afforded the product **8** as a pale yellow solid (36 mg, 46%, > 20:1 dr) along with the final product **5I** (21 mg, 26%). R_f (Acetone/Dichloromethane : 2/8) = 0.33. **Mp** 108-110 °C. ^{13}C NMR



(100 MHz, δ ppm/ DMSO- d_6): 192.9 (C), 177.4 (C), 165.6 (d, J_{C-F} = 251.3 Hz, C), 142.3 (C), 137.6 (C), 134.2 (d, J_{C-P} = 223.1 Hz, C), 131.4 (d, J_{C-F} = 9.8 Hz, CH), 131.3 (d, J_{C-F} = 9.8 Hz, CH), 130.3 (C), 126.3 (CH), 125.5 (CH), 122.2 (CH), 116.3 (d, J_{C-F} = 21.3 Hz, CH), 116.0 (d, J_{C-F} = 21.3 Hz, CH), 110.2 (CH), 72.2 (d, J_{C-P} = 4.0 Hz, C), 62.1 (d, J_{C-P} = 21.3 Hz, CH), 53.6 (d, J_{C-P} = 5.6 Hz, CH₃), 53.2 (d, J_{C-P} = 5.5 Hz, CH₃). 1H NMR (400 MHz, δ ppm/DMSO- d_6): 10.60 (s, 1H), 9.07 (s, 1H), 7.66-7.63 (m, 2H), 7.15 (t, J = 8.8 Hz, 2H), 7.02 (t, J = 7.4 Hz, 1H), 6.81 (d, J = 7.2 Hz, 1H), 6.75 (t, J = 7.6 Hz, 1H), 6.63 (d, J = 7.6 Hz, 1H), 5.35 (s, 1H), 3.76 (d, J = 11.2 Hz, 3H), 3.67 (d, J = 11.2 Hz, 3H).





































3g



161.9 MHz/DMSO-d₆







3h



400 MHz/DMSO-d₆





















3k



161.9 MHz/DMSO-d₆









3l



400 MHz/DMSO-d₆

























161.9 MHz/DMSO-d₆







400 MHz/DMSO-d₆














































































100 MHz/DMSO-d₆161.9 MHz/DMSO-d₆




























































5u

161.9 MHz/DMSO-d₆



5v

400 MHz/DMSO-d₆

